Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

With new approvals on the horizon and the closely watched Casgevy launch picking up steam in sickle cell disease and beta ...

Orsini has been chosen by Vertex Pharmaceuticals Incorporated to dispense gene-editing therapy CASGEVY® (exagamglogene ...

Phase 1 data indicate Intellia’s medicine could be a powerful treatment for a cardiac form of ATTR amyloidosis. But rival drugs are further ahead.

It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.

I also expect both to become huge commercial successes for Vertex. Second, the big biotech company's launch of Casgevy is ...

We recently compiled a list of the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2024. In this article, we are going to ...

With a bunch of gene therapy and gene editing programs in clinical trials, CRISPR Therapeutics (NASDAQ: CRSP) has an ...

Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (NASDAQ: VKTX), a mid ...

The launch of Casgevy, CRISPR Therapeutics' gene therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), represents a significant milestone for the company.